Delivering the right medicine, to the right patient, at the right time.
Clinigen is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines.
1. Culture: Develop and retain talented people
2019 Progress
- 29 employees completed the Clinigen Management Academy training program
- Long service recognition awards introduced globally
- Launched online survey tool for employees, providing weekly engagement data
Performance Metrics
- Employee engagement score: 7.1
2020 Objectives
- Launch a bespoke leadership development program
- Introduce a global employee wellbeing initiative
- Improve engagement and retention levels
2. Technology: Upgrade technology platform to drive organic growth
2019 Progress
- Growth of Cliniport (proprietary web-based operating system) enabling the Group to better interact with the customer
- Launch of Clinigen Direct, a new digital service offering for HCPs to source hard to access medicines
- Continued implementation of Clinigen One ERP modules
Performance Metrics
- Number of products available on Cliniport and Clinigen Direct: >1,800
2020 Objectives
- Complete implementation of Clinigen One ERP
- Increase number of programs and products available on Cliniport and Clinigen Direct
- Embed Cliniport and Clinigen Direct functionality including extended real world data (‘RWD’) capability
3. Customer: Expand and embed a global community of HCPS and opinion leaders
2019 Progress
- Growth of Cliniport (proprietary web-based operating system) enabling the Group to better interact with the customer
- Launch of Clinigen Direct, a new digital service offering for HCPs to source hard to access medicines
- Building out US commercial infrastructure following acquisition of Proleukin
- EU MSL capability through acquisition of iQone will help interaction with HCP customers
Performance Metrics
2020 Objectives
- Increase number of users and amount of activity through Cliniport and Clinigen Direct
- Expand MSL and commercial capability in the US and the EU
- Drive Key Opinion Leader (‘KOL’), hospital pharmacist and pharmacy group engagement across markets
4. Business: Expand portfolio of global, regional and licensed assets
2019 Progress
- Acquisition of Proleukin and Imukin strengthen our offering in Commercial Medicines
- Approval of Foscavir for the treatment of HHV-6 in Japan
- Launch of Melatonin demonstrating further success of the UL2L development pipeline
- Exclusive licensing agreement signed with GC Pharma in Japan. Clinigen’s first such agreement in Japan
Performance Metrics
2020 Objectives
- Further conversion of UL2L pipeline
- Internationalisation of developed commercial product portfolio
- Continue to search for selective acquisitions
- Conversion of MAPs to regional licensing opportunities
5. Business: Become the 'go to' global leader in ethical access to unlicensed medicines
2019 Progress
- Acquisition of CSM reinforces links between Clinical Services and Unlicensed Medicines
- Acquisition of iQone provides MSL capability, a key differentiator in the Managed Access business within Unlicensed Medicines from its competitors
- Increase in number of MAPs and exclusive Global Access client supply agreements
- Launch of Clinigen Direct, a new digital service offering for HCPs to source hard to access medicines
Performance Metrics
2020 Objectives
- Expand and deepen our client base in Managed Access
- Develop our portfolio of exclusive supply agreements
- Build an excellence in Customer Services
- Leverage Group sourcing and procurement capability
6. Business: Extend global footprint into remaining key markets
2019 Progress
- Acquisition of Proleukin provides an ideal platform to expand existing footprint in the US
- Acquisition of CSM provides important EU infrastructure
- Acquisition of iQone helps support Clinigen’s Commercial Medicines portfolio in key EU markets
- Partnership agreement with Accord signed to supply and distribute Cardioxane and Savene in Poland
Performance Metrics
2020 Objectives
- Further partnership agreements signed to expand geographical reach, particularly in the LATAM and the Middle East
- Further expansion of commercial infrastructure in US and EU
7. Business: Link to Businesses to realise synergistic opportunities and increase pharmaceutical customer base
2019 Progress
- Acquisition of CSM increases the size of the customer base at an early stage of product lifecycle and additional capabilities have enhanced proposition across the Group’s three business operations
- Acquisition of iQone provides capability to partner with pharmaceutical and biotech companies to commercialise products earlier in the lifecycle and support partner company products
- Creation of Group Heads of Business Development Network to work more effectively and realise links between the businesses
Performance Metrics
- Number of top 50 pharmaceutical companies who have worked with all three business operations: 5
2020 Objectives
- Embed a culture that seeks to maximise value through extending product commercial relationships through the lifecycle
- Increase the number of top 50 companies working with all business operations
- Increase the number of companies working with at least two business operations
- Ensure alignment of objectives across business divisions and support functions with scorecards developed at each level